ProCE Banner Activity

My Take on 3 Interesting ART Reports From AIDS 2020: Virtual

Conference Coverage
Clinical Thought
Current HIV treatment options are highly safe and effective, but there is still room for improvement and for more information on optimizing ART, including the need for more data on initial ART approaches for patients who present with advanced HIV infection, simplified strategies that reduce drug burden, and the best approach for NRTI selection in second-line therapy. Here’s my take on data from 3 studies addressing these important topics, as reported at AIDS 2020: Virtual.

Released: August 28, 2020

Expiration: August 27, 2021

No longer available for credit.

Share

Faculty

José R. Arribas

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

AIDS 2020

ProCE Banner

IAS 2018

ProCE Banner

Faculty Disclosure

Primary Author

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

José R. Arribas, MD, has disclosed that he has received consulting fees from Aelix, Gilead Sciences, Janssen, Merck, Teva, and ViiV Healthcare and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.